"rationale","uuid:ID","studyTitle","versionIdentifier","studyAcronym","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ae80776a-5af3-4f7e-b0fc-d03bc99f4ef3","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","LZZT","StudyVersion_1"
